We serve Chemical Name:4,6-O-Benzylidene-D-glucal CAS:63598-36-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4,6-O-Benzylidene-D-glucal
CAS.NO:63598-36-7
Synonyms:4,6-o-benzylidene-d-glucal
Molecular Formula:C13H14O4
Molecular Weight:234.24800
HS Code:2932999099
Physical and Chemical Properties:
Melting point:138-143ºC
Boiling point:420.9ºC at 760 mmHg
Density:1.259g/cm3
Index of Refraction:1.567
PSA:47.92000
Exact Mass:234.08900
LogP:1.37400
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4,6-o-benzylidene-d-glucal chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,6-o-benzylidene-d-glucal physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,6-o-benzylidene-d-glucal Use and application,4,6-o-benzylidene-d-glucal technical grade,usp/ep/jp grade.
Related News: The continuous acceleration of the industrial transfer process has provided a huge market space for the fine chemical intermediate industry. 4,6-O-Benzylidene-D-glucal manufacturer AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. 4,6-O-Benzylidene-D-glucal supplier The drug, Imfinzi, when added to chemotherapy and the drugmaker��s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said. 4,6-O-Benzylidene-D-glucal vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 4,6-O-Benzylidene-D-glucal factory AXON is planning a follow-up trial that will include a better-defined group of Alzheimer’s patients suffering from both amyloid plaques and tau tangles, Novak said.
